China First Domestic COVID-19 Antibody Therapy Moves Towards Green Light
Strong Overseas Efficacy Data
Executive Summary
Brii’s antibody combo therapy nears approval in China, based on data from a late-stage study conducted outside the country.
You may also be interested in...
China Touts First COVID Antibody Approval But Border Opening Eludes
The first antibody approval for COVID-19 in China comes amid variant threats and a continued strict Zero COVID policy.
Coronavirus Update: Brii Files US EUA For Antibody Combo
Chinese venture Brii seeks US emergency authorization for its antibody combo, as Chugai aims for wider use of its antibody cocktail in Japan and two other Chinese firms link up on an oral antiviral.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.